Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2016-03-02 Director's Dealing
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2016-03-02 English
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as officers or directors. It details transactions in the company's shares by a senior vice president, including acquisitions and dispositions. This type of filing is specifically related to insider trading disclosures and personal share transactions by company executives. According to the filing definitions, this corresponds to Director's Dealing (DIRS). The document is not a financial report, earnings release, or any other type of corporate report but a regulatory filing about insider share transactions.
2016-03-02 English
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of securities by company insiders such as officers or directors. It details transactions in the company's shares by an executive (Executive Vice President) including dates, amounts, and prices. This type of filing is specifically related to insider trading disclosures and personal share transactions by company directors and executives. It is not a financial report, earnings release, or any other type of corporate report. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on insider transactions, confirming this classification with high confidence.
2016-03-02 English
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as officers or directors. It details transactions in the company's shares by a reporting person, including dates, amounts, and nature of ownership. This type of filing is specifically used to report insider trades and changes in ownership by directors and executives. It is not a financial report, earnings release, or any other type of corporate report. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is the actual Form 4 filing, not an announcement or certification.
2016-03-02 English
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled 'SEC FORM 4' and is a 'Statement of Changes in Beneficial Ownership' filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. It details transactions by an officer (Executive Vice President) of Abbott Laboratories, including dates, transaction codes, and amounts of securities acquired or disposed of. This type of filing is a report of personal share transactions by company directors and executives, commonly known as insider trading reports. It is not an annual report, earnings release, or any other financial or governance report. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 4151 characters, which is typical for such filings, and it contains detailed transaction data rather than just an announcement or certification.
2016-03-02 English
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as officers or directors. It details transactions in the company's shares by an executive (Stephen R. Fussell, Executive Vice President of Abbott Laboratories). Form 4 filings are specifically used to report insider trades and changes in ownership by company insiders. This matches the definition of Director's Dealing (DIRS). The document is not an announcement or summary but the actual filing of insider transactions. Therefore, the correct classification is DIRS with high confidence.
2016-03-02 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.